Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.

Case reports in oncology

Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC.
PMID: 25848355
Case Rep Oncol. 2015 Feb 12;8(1):72-7. doi: 10.1159/000375293. eCollection 2015.

BACKGROUND: Survival of patients with leptomeningeal metastases (LM) and impaired functional status is limited to several months, and rarely does neurological function improve with treatment.CASE REPORT: A 34-year-old female with hormone-negative and HER2-positive metastatic breast cancer was diagnosed with...

Cite
Le Rhun E, Taillibert S, Boulanger T, et al. Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Rep Oncol. 2015;8(1):72-7doi: 10.1159/000375293.
Le Rhun, E., Taillibert, S., Boulanger, T., Zairi, F., Bonneterre, J., & Chamberlain, M. C. (2015). Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case reports in oncology, 8(1), 72-7. https://doi.org/10.1159/000375293
Le Rhun, Emilie, et al. "Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases." Case reports in oncology vol. 8,1 (2015): 72-7. doi: https://doi.org/10.1159/000375293
Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC. Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Rep Oncol. 2015 Feb 12;8(1):72-7. doi: 10.1159/000375293. eCollection 2015. PMID: 25848355; PMCID: PMC4361905.
Copy Download .nbib Format: NLM
Geographic dimensions of a health network dedicated to occupational and work related diseases.

International journal of health geographics

Delaunay M, Godard V, Le Barbier M, Gilg Soit Ilg A, Aubert C, Maître A, Barbeau D, Bonneterre V.
PMID: 27678070
Int J Health Geogr. 2016 Sep 27;15(1):34. doi: 10.1186/s12942-016-0063-7.

BACKGROUND: Although introduced nearly 40 years ago, Geographic Information Systems (GISs) have never been used to study Occupational Health information regarding the different types, scale or sources of data. The geographic distribution of occupational diseases and underlying work activities...

Cite
Delaunay M, Godard V, Le Barbier M, et al. Geographic dimensions of a health network dedicated to occupational and work related diseases. Int J Health Geogr. 2016;15(1):34doi: 10.1186/s12942-016-0063-7.
Delaunay, M., Godard, V., Le Barbier, M., Gilg Soit Ilg, A., Aubert, C., Maître, A., Barbeau, D., & Bonneterre, V. (2016). Geographic dimensions of a health network dedicated to occupational and work related diseases. International journal of health geographics, 15(1), 34. https://doi.org/10.1186/s12942-016-0063-7
Delaunay, Marie, et al. "Geographic dimensions of a health network dedicated to occupational and work related diseases." International journal of health geographics vol. 15,1 (2016): 34. doi: https://doi.org/10.1186/s12942-016-0063-7
Delaunay M, Godard V, Le Barbier M, Gilg Soit Ilg A, Aubert C, Maître A, Barbeau D, Bonneterre V. Geographic dimensions of a health network dedicated to occupational and work related diseases. Int J Health Geogr. 2016 Sep 27;15(1):34. doi: 10.1186/s12942-016-0063-7. PMID: 27678070; PMCID: PMC5039888.
Copy Download .nbib Format: NLM
Synthesis of dihydrophenanthridines by a sequence of Ugi-4CR and palladium-catalyzed intramolecular C-H functionalization.

Beilstein journal of organic chemistry

Bonnaterre F, Bois-Choussy M, Zhu J.
PMID: 18665200
Beilstein J Org Chem. 2008 Apr 08;4:10. doi: 10.3762/bjoc.4.10.

BACKGROUND: Small polyfunctionalized heterocyclic compounds play important roles in the drug discovery process and in the isolation and structural identification of biological macromolecules. It is expected that ready access to diverse sets of heterocycles can not only help improving...

Cite
Bonnaterre F, Bois-Choussy M, Zhu J. Synthesis of dihydrophenanthridines by a sequence of Ugi-4CR and palladium-catalyzed intramolecular C-H functionalization. Beilstein J Org Chem. 2008;4:10doi: 10.3762/bjoc.4.10.
Bonnaterre, F., Bois-Choussy, M., & Zhu, J. (2008). Synthesis of dihydrophenanthridines by a sequence of Ugi-4CR and palladium-catalyzed intramolecular C-H functionalization. Beilstein journal of organic chemistry, 410. https://doi.org/10.3762/bjoc.4.10
Bonnaterre, Florence, et al. "Synthesis of dihydrophenanthridines by a sequence of Ugi-4CR and palladium-catalyzed intramolecular C-H functionalization." Beilstein journal of organic chemistry vol. 4 (2008): 10. doi: https://doi.org/10.3762/bjoc.4.10
Bonnaterre F, Bois-Choussy M, Zhu J. Synthesis of dihydrophenanthridines by a sequence of Ugi-4CR and palladium-catalyzed intramolecular C-H functionalization. Beilstein J Org Chem. 2008 Apr 08;4:10. doi: 10.3762/bjoc.4.10. PMID: 18665200; PMCID: PMC2395297.
Copy Download .nbib Format: NLM
Reuse of medical face masks in domestic and community settings without sacrificing safety: Ecological and economical lessons from the Covid-19 pandemic.

Chemosphere

Alcaraz JP, Le Coq L, Pourchez J, Thomas D, Chazelet S, Boudry I, Barbado M, Silvent S, Dessale C, Antoine F, Guimier-Pingault C, Cortella L, Rouif S, Bardin-Monnier N, Charvet A, Dufaud O, Leclerc L, Montigaud Y, Laurent C, Verhoeven P, Joubert A, Bouhanguel A, Andres Y, Gaffé J, Martin DK, Huet C, Boisset S, Maurin M, Rumeau P, Charlot F, Richaud E, Moreau-Gaudry A, Bonneterre V, Cinquin P, Landelle C.
PMID: 34600007
Chemosphere. 2022 Feb;288:132364. doi: 10.1016/j.chemosphere.2021.132364. Epub 2021 Sep 29.

The need for personal protective equipment increased exponentially in response to the Covid-19 pandemic. To cope with the mask shortage during springtime 2020, a French consortium was created to find ways to reuse medical and respiratory masks in healthcare...

Cite
Alcaraz JP, Le Coq L, Pourchez J, et al. Reuse of medical face masks in domestic and community settings without sacrificing safety: Ecological and economical lessons from the Covid-19 pandemic. Chemosphere. 2021;288:132364doi: 10.1016/j.chemosphere.2021.132364.
Alcaraz, J. P., Le Coq, L., Pourchez, J., Thomas, D., Chazelet, S., Boudry, I., Barbado, M., Silvent, S., Dessale, C., Antoine, F., Guimier-Pingault, C., Cortella, L., Rouif, S., Bardin-Monnier, N., Charvet, A., Dufaud, O., Leclerc, L., Montigaud, Y., Laurent, C., Verhoeven, P., Joubert, A., Bouhanguel, A., Andres, Y., Gaffé, J., Martin, D. K., Huet, C., Boisset, S., Maurin, M., Rumeau, P., Charlot, F., Richaud, E., Moreau-Gaudry, A., Bonneterre, V., Cinquin, P., & Landelle, C. (2022). Reuse of medical face masks in domestic and community settings without sacrificing safety: Ecological and economical lessons from the Covid-19 pandemic. Chemosphere, 288132364. https://doi.org/10.1016/j.chemosphere.2021.132364
Alcaraz, Jean-Pierre, et al. "Reuse of medical face masks in domestic and community settings without sacrificing safety: Ecological and economical lessons from the Covid-19 pandemic." Chemosphere vol. 288 (2022): 132364. doi: https://doi.org/10.1016/j.chemosphere.2021.132364
Alcaraz JP, Le Coq L, Pourchez J, Thomas D, Chazelet S, Boudry I, Barbado M, Silvent S, Dessale C, Antoine F, Guimier-Pingault C, Cortella L, Rouif S, Bardin-Monnier N, Charvet A, Dufaud O, Leclerc L, Montigaud Y, Laurent C, Verhoeven P, Joubert A, Bouhanguel A, Andres Y, Gaffé J, Martin DK, Huet C, Boisset S, Maurin M, Rumeau P, Charlot F, Richaud E, Moreau-Gaudry A, Bonneterre V, Cinquin P, Landelle C. Reuse of medical face masks in domestic and community settings without sacrificing safety: Ecological and economical lessons from the Covid-19 pandemic. Chemosphere. 2022 Feb;288:132364. doi: 10.1016/j.chemosphere.2021.132364. Epub 2021 Sep 29. PMID: 34600007; PMCID: PMC8491628.
Copy Download .nbib Format: NLM
Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis.

BMC clinical pathology

Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt Mde C, Faure GC.
PMID: 23145812
BMC Clin Pathol. 2012 Nov 12;12:21. doi: 10.1186/1472-6890-12-21.

BACKGROUND: The diagnosis of leptomeningeal metastasis (LM) in patients with solid tumors remains difficult. The usual diagnostic methods of cytomorphological assessment of cerebro-spinal fluid (CSF) and gadolinium enhanced MRI of the entire neuraxis lack both specificity and sensitivity. The...

Cite
Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12:21doi: 10.1186/1472-6890-12-21.
Le Rhun, E., Massin, F., Tu, Q., Bonneterre, J., Bittencourt, M. d. e. . C., & Faure, G. C. (2012). Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC clinical pathology, 1221. https://doi.org/10.1186/1472-6890-12-21
Le Rhun, Emilie, et al. "Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis." BMC clinical pathology vol. 12 (2012): 21. doi: https://doi.org/10.1186/1472-6890-12-21
Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt Mde C, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012 Nov 12;12:21. doi: 10.1186/1472-6890-12-21. PMID: 23145812; PMCID: PMC3539901.
Copy Download .nbib Format: NLM
High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer.

Oncology letters

Pannier D, Philippin-Lauridant G, Baranzelli MC, Bertin D, Bogart E, Delprat V, Villain G, Mattot V, Bonneterre J, Soncin F.
PMID: 27446447
Oncol Lett. 2016 Aug;12(2):1422-1428. doi: 10.3892/ol.2016.4791. Epub 2016 Jun 28.

Tumor blood vessels participate in the immune response against cancer cells and we previously used pre-clinical models to demonstrate that egfl7 (VE-statin) promotes tumor cell evasion from the immune system by repressing endothelial cell activation, preventing immune cells from...

Cite
Pannier D, Philippin-Lauridant G, Baranzelli MC, et al. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. Oncol Lett. 2016;12(2):1422-1428doi: 10.3892/ol.2016.4791.
Pannier, D., Philippin-Lauridant, G., Baranzelli, M. C., Bertin, D., Bogart, E., Delprat, V., Villain, G., Mattot, V., Bonneterre, J., & Soncin, F. (2016). High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. Oncology letters, 12(2), 1422-1428. https://doi.org/10.3892/ol.2016.4791
Pannier, Diane, et al. "High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer." Oncology letters vol. 12,2 (2016): 1422-1428. doi: https://doi.org/10.3892/ol.2016.4791
Pannier D, Philippin-Lauridant G, Baranzelli MC, Bertin D, Bogart E, Delprat V, Villain G, Mattot V, Bonneterre J, Soncin F. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. Oncol Lett. 2016 Aug;12(2):1422-1428. doi: 10.3892/ol.2016.4791. Epub 2016 Jun 28. PMID: 27446447; PMCID: PMC4950557.
Copy Download .nbib Format: NLM
Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics.

Safety and health at work

Bonneterre V, Bicout DJ, de Gaudemaris R.
PMID: 22993712
Saf Health Work. 2012 Jun;3(2):92-100. doi: 10.5491/SHAW.2012.3.2.92. Epub 2012 Jun 08.

OBJECTIVES: The French National Occupational Diseases Surveillance and Prevention Network (RNV3P) is a French network of occupational disease specialists, which collects, in standardised coded reports, all cases where a physician of any specialty, referred a patient to a university...

Cite
Bonneterre V, Bicout DJ, de Gaudemaris R. Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics. Saf Health Work. 2012;3(2):92-100doi: 10.5491/SHAW.2012.3.2.92.
Bonneterre, V., Bicout, D. J., & de Gaudemaris, R. (2012). Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics. Safety and health at work, 3(2), 92-100. https://doi.org/10.5491/SHAW.2012.3.2.92
Bonneterre, Vincent, et al. "Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics." Safety and health at work vol. 3,2 (2012): 92-100. doi: https://doi.org/10.5491/SHAW.2012.3.2.92
Bonneterre V, Bicout DJ, de Gaudemaris R. Application of pharmacovigilance methods in occupational health surveillance: comparison of seven disproportionality metrics. Saf Health Work. 2012 Jun;3(2):92-100. doi: 10.5491/SHAW.2012.3.2.92. Epub 2012 Jun 08. PMID: 22993712; PMCID: PMC3440466.
Copy Download .nbib Format: NLM
Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.

ESMO open

Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O'Shaughnessy J.
PMID: 27843626
ESMO Open. 2016 Aug 22;1(4):e000072. doi: 10.1136/esmoopen-2016-000072. eCollection 2016.

BACKGROUND: The progesterone receptor (PR) is expressed by ∼70% of early breast tumours and is implicated in the progression of breast cancer. In cancerous tissues PR may be activated in the absence of a ligand, or when ligand concentrations...

Cite
Bonneterre J, Bosq J, Jamme P, et al. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016;1(4):e000072doi: 10.1136/esmoopen-2016-000072.
Bonneterre, J., Bosq, J., Jamme, P., Valent, A., Gilles, E. M., Zukiwski, A. A., Fuqua, S. A., Lange, C. A., & O'Shaughnessy, J. (2016). Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO open, 1(4), e000072. https://doi.org/10.1136/esmoopen-2016-000072
Bonneterre, Jacques, et al. "Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort." ESMO open vol. 1,4 (2016): e000072. doi: https://doi.org/10.1136/esmoopen-2016-000072
Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O'Shaughnessy J. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016 Aug 22;1(4):e000072. doi: 10.1136/esmoopen-2016-000072. eCollection 2016. PMID: 27843626; PMCID: PMC5070234.
Copy Download .nbib Format: NLM
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?.

Breast (Edinburgh, Scotland)

Héry M, Delozier T, Ramaioli A, Julien JP, de Lafontan B, Petit T, de Ghislain C, Weber B, Bonneterre J, Teissier E.
PMID: 14965709
Breast. 2002 Oct;11(5):442-8. doi: 10.1054/brst.2002.0462.

The purpose of this study was to determine a subpopulation of node-negative breast cancer patients at high risk of metastases and to analyse the relationship between conventional prognostic factors and the onset of metastatic disease. Patients with node-negative breast...

Cite
Héry M, Delozier T, Ramaioli A, et al. Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?. Breast. 2002;11(5):442-8doi: 10.1054/brst.2002.0462.
Héry, M., Delozier, T., Ramaioli, A., Julien, J. P., de Lafontan, B., Petit, T., de Ghislain, C., Weber, B., Bonneterre, J., & Teissier, E. (2002). Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?. Breast (Edinburgh, Scotland), 11(5), 442-8. https://doi.org/10.1054/brst.2002.0462
Héry, Michel, et al. "Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?." Breast (Edinburgh, Scotland) vol. 11,5 (2002): 442-8. doi: https://doi.org/10.1054/brst.2002.0462
Héry M, Delozier T, Ramaioli A, Julien JP, de Lafontan B, Petit T, de Ghislain C, Weber B, Bonneterre J, Teissier E. Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?. Breast. 2002 Oct;11(5):442-8. doi: 10.1054/brst.2002.0462. PMID: 14965709.
Copy Download .nbib Format: NLM
ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.

SpringerPlus

Dumont A, Pannier D, Ducoulombier A, Tresch E, Chen J, Kramar A, Révillion F, Peyrat JP, Bonneterre J.
PMID: 26180747
Springerplus. 2015 Jul 07;4:327. doi: 10.1186/s40064-015-1053-0. eCollection 2015.

PURPOSE: Neoadjuvant chemotherapy (NCT) using anthracyclines and taxanes is a standard treatment for locally advanced breast cancer. Efficacy of NCT is however variable among patients and predictive markers are expected to guide the selection of patients who will benefit...

Cite
Dumont A, Pannier D, Ducoulombier A, et al. ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. Springerplus. 2015;4:327doi: 10.1186/s40064-015-1053-0.
Dumont, A., Pannier, D., Ducoulombier, A., Tresch, E., Chen, J., Kramar, A., Révillion, F., Peyrat, J. P., & Bonneterre, J. (2015). ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. SpringerPlus, 4327. https://doi.org/10.1186/s40064-015-1053-0
Dumont, Aurélie, et al. "ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors." SpringerPlus vol. 4 (2015): 327. doi: https://doi.org/10.1186/s40064-015-1053-0
Dumont A, Pannier D, Ducoulombier A, Tresch E, Chen J, Kramar A, Révillion F, Peyrat JP, Bonneterre J. ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. Springerplus. 2015 Jul 07;4:327. doi: 10.1186/s40064-015-1053-0. eCollection 2015. PMID: 26180747; PMCID: PMC4493257.
Copy Download .nbib Format: NLM
Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.

The International journal of biological markers

Revillion F, Lhotellier V, Hornez L, Leroy A, Baranzelli MC, Giard S, Bonneterre J, Peyrat JP.
PMID: 28207102
Int J Biol Markers. 2008 Jan - Mar;23(1):10-17. doi: 10.5301/JBM.2008.2066.

At the Centre Oscar Lambret, the anticancer centre of the North of France, sentinel lymph node (SLN) procedures are routinely performed for localized (T0-T1, N0, M0) breast carcinoma without any previous treatment, in order to prevent the deleterious effects...

Cite
Revillion F, Lhotellier V, Hornez L, et al. Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int J Biol Markers. 2008;23(1):10-17doi: 10.5301/JBM.2008.2066.
Revillion, F., Lhotellier, V., Hornez, L., Leroy, A., Baranzelli, M. C., Giard, S., Bonneterre, J., & Peyrat, J. P. (2008). Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. The International journal of biological markers, 23(1), 10-17. https://doi.org/10.5301/JBM.2008.2066
Revillion, F, et al. "Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion." The International journal of biological markers vol. 23,1 (2008): 10-17. doi: https://doi.org/10.5301/JBM.2008.2066
Revillion F, Lhotellier V, Hornez L, Leroy A, Baranzelli MC, Giard S, Bonneterre J, Peyrat JP. Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int J Biol Markers. 2008 Jan - Mar;23(1):10-17. doi: 10.5301/JBM.2008.2066. PMID: 28207102.
Copy Download .nbib Format: NLM
Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.

Oncotarget

Jobard E, Trédan O, Bachelot T, Vigneron AM, Aït-Oukhatar CM, Arnedos M, Rios M, Bonneterre J, Diéras V, Jimenez M, Merlin JL, Campone M, Elena-Herrmann B.
PMID: 29137365
Oncotarget. 2017 Jun 28;8(48):83570-83584. doi: 10.18632/oncotarget.18784. eCollection 2017 Oct 13.

The mammalian target of rapamycin complex 1 (mTORC1) is an attractive target for HER-2 positive breast cancer therapy because of its key role in protein translation regulation, cell growth and metabolism. We present here a metabolomic investigation exploring the...

Cite
Jobard E, Trédan O, Bachelot T, et al. Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget. 2017;8(48):83570-83584doi: 10.18632/oncotarget.18784.
Jobard, E., Trédan, O., Bachelot, T., Vigneron, A. M., Aït-Oukhatar, C. M., Arnedos, M., Rios, M., Bonneterre, J., Diéras, V., Jimenez, M., Merlin, J. L., Campone, M., & Elena-Herrmann, B. (2017). Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget, 8(48), 83570-83584. https://doi.org/10.18632/oncotarget.18784
Jobard, Elodie, et al. "Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients." Oncotarget vol. 8,48 (2017): 83570-83584. doi: https://doi.org/10.18632/oncotarget.18784
Jobard E, Trédan O, Bachelot T, Vigneron AM, Aït-Oukhatar CM, Arnedos M, Rios M, Bonneterre J, Diéras V, Jimenez M, Merlin JL, Campone M, Elena-Herrmann B. Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. Oncotarget. 2017 Jun 28;8(48):83570-83584. doi: 10.18632/oncotarget.18784. eCollection 2017 Oct 13. PMID: 29137365; PMCID: PMC5663537.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries